A PYMNTS Company

Amgen, Teva Get Can Appeal Sensipar Antitrust Ruling

By  |  April 9, 2023

Amgen and Teva Pharmaceuticals Industries have been granted permission for an expedited appeal in an antitrust case related to Amgen’s Sensipar, a calcium reducer, after a lower court decision.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    According to a memorandum by Judge Colm F. Connolly in the US District Court for the District of Delaware, pharmaceutical companies have the right to appeal a decision if he finds that he does not have the authority to allow an interlocutory appeal of a previous judge’s ruling.

    Related: Warren Sends Letter To FTC Over Amgen & Indivior Deals

    There is “substantial ground for difference of opinion” about whether a judge can certify for interlocutory appeal another judge’s order in the same case, Connolly said.